Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.05
TMO's Cash-to-Debt is ranked lower than
96% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. TMO: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
TMO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.36 Max: 2.34
Current: 0.05
0.03
2.34
Equity-to-Asset 0.48
TMO's Equity-to-Asset is ranked lower than
73% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. TMO: 0.48 )
Ranked among companies with meaningful Equity-to-Asset only.
TMO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.48 Max: 0.75
Current: 0.48
0.31
0.75
Debt-to-Equity 0.73
TMO's Debt-to-Equity is ranked lower than
77% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. TMO: 0.73 )
Ranked among companies with meaningful Debt-to-Equity only.
TMO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09  Med: 0.65 Max: 1.3
Current: 0.73
0.09
1.3
Debt-to-EBITDA 3.45
TMO's Debt-to-EBITDA is ranked lower than
77% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. TMO: 3.45 )
Ranked among companies with meaningful Debt-to-EBITDA only.
TMO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.99  Med: 3.17 Max: 4.16
Current: 3.45
0.99
4.16
Interest Coverage 5.23
TMO's Interest Coverage is ranked lower than
80% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. TMO: 5.23 )
Ranked among companies with meaningful Interest Coverage only.
TMO' s Interest Coverage Range Over the Past 10 Years
Min: 3.97  Med: 6.46 Max: 14.74
Current: 5.23
3.97
14.74
Piotroski F-Score: 6
Altman Z-Score: 3.05
Beneish M-Score: -2.42
WACC vs ROIC
9.78%
6.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 14.85
TMO's Operating Margin % is ranked higher than
79% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. TMO: 14.85 )
Ranked among companies with meaningful Operating Margin % only.
TMO' s Operating Margin % Range Over the Past 10 Years
Min: 10.98  Med: 12.28 Max: 14.65
Current: 14.85
10.98
14.65
Net Margin % 10.36
TMO's Net Margin % is ranked higher than
80% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. TMO: 10.36 )
Ranked among companies with meaningful Net Margin % only.
TMO' s Net Margin % Range Over the Past 10 Years
Min: 8.41  Med: 10.3 Max: 11.64
Current: 10.36
8.41
11.64
ROE % 9.57
TMO's ROE % is ranked higher than
69% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. TMO: 9.57 )
Ranked among companies with meaningful ROE % only.
TMO' s ROE % Range Over the Past 10 Years
Min: 5.6  Med: 8.32 Max: 10.13
Current: 9.57
5.6
10.13
ROA % 4.41
TMO's ROA % is ranked higher than
69% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. TMO: 4.41 )
Ranked among companies with meaningful ROA % only.
TMO' s ROA % Range Over the Past 10 Years
Min: 3.98  Med: 4.65 Max: 5.52
Current: 4.41
3.98
5.52
ROC (Joel Greenblatt) % 48.41
TMO's ROC (Joel Greenblatt) % is ranked higher than
84% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. TMO: 48.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TMO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 37.47  Med: 45.21 Max: 62.88
Current: 48.41
37.47
62.88
3-Year Revenue Growth Rate 7.80
TMO's 3-Year Revenue Growth Rate is ranked higher than
58% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. TMO: 7.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TMO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12.9  Med: 7.3 Max: 18.7
Current: 7.8
-12.9
18.7
3-Year EBITDA Growth Rate 6.30
TMO's 3-Year EBITDA Growth Rate is ranked lower than
56% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. TMO: 6.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TMO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -13.6  Med: 14.6 Max: 33.8
Current: 6.3
-13.6
33.8
3-Year EPS without NRI Growth Rate 5.90
TMO's 3-Year EPS without NRI Growth Rate is ranked lower than
58% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. TMO: 5.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TMO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -43.5  Med: 13.4 Max: 74.6
Current: 5.9
-43.5
74.6
GuruFocus has detected 4 Warning Signs with Thermo Fisher Scientific Inc TMO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TMO's 30-Y Financials

Financials (Next Earnings Date: 2018-10-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

TMO Guru Trades in Q3 2017

Jeremy Grantham 1,700 sh (New)
First Eagle Investment 350,584 sh (+175192.00%)
David Tepper 592,000 sh (+57.87%)
Diamond Hill Capital 1,075,604 sh (+50.50%)
Mario Gabelli 49,030 sh (+14.12%)
Pioneer Investments 2,247,958 sh (+0.24%)
Wallace Weitz 131,725 sh (+0.14%)
Vanguard Health Care Fund 3,535,100 sh (unchged)
Robert Olstein 23,000 sh (unchged)
Prem Watsa 1,344 sh (unchged)
Caxton Associates 3,300 sh (unchged)
Ray Dalio Sold Out
Jim Simons Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
John Rogers 384,317 sh (-0.45%)
Larry Robbins 2,728,827 sh (-1.13%)
Ken Fisher 1,265 sh (-1.48%)
PRIMECAP Management 5,200,280 sh (-1.57%)
Dodge & Cox 45,737 sh (-4.09%)
Mairs and Power 1,570 sh (-6.71%)
Steven Romick 1,042,910 sh (-8.11%)
First Pacific Advisors 1,329,880 sh (-9.07%)
Signature Select Canadian Fund 36,850 sh (-17.84%)
Manning & Napier Advisors, Inc 171,095 sh (-37.03%)
Steven Cohen 35,000 sh (-72.35%)
Eaton Vance Worldwide Health Sciences Fund 157,958 sh (-18.65%)
» More
Q4 2017

TMO Guru Trades in Q4 2017

Andreas Halvorsen 814,517 sh (New)
George Soros 57,500 sh (New)
Jeremy Grantham 3,800 sh (+123.53%)
Ken Fisher 2,070 sh (+63.64%)
Larry Robbins 3,327,576 sh (+21.94%)
Diamond Hill Capital 1,101,027 sh (+2.36%)
First Pacific Advisors 1,338,070 sh (+0.62%)
Steven Romick 1,042,910 sh (unchged)
Robert Olstein 23,000 sh (unchged)
Prem Watsa 1,344 sh (unchged)
Wallace Weitz 131,725 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 157,958 sh (unchged)
Caxton Associates Sold Out
Steven Cohen Sold Out
PRIMECAP Management 5,144,244 sh (-1.08%)
Pioneer Investments 2,185,997 sh (-2.76%)
David Tepper 572,000 sh (-3.38%)
John Rogers 370,944 sh (-3.48%)
Dodge & Cox 43,937 sh (-3.94%)
Vanguard Health Care Fund 3,389,165 sh (-4.13%)
Mairs and Power 1,460 sh (-7.01%)
Mario Gabelli 45,275 sh (-7.66%)
First Eagle Investment 200 sh (-99.94%)
» More
Q1 2018

TMO Guru Trades in Q1 2018

Jim Simons 362,744 sh (New)
Leon Cooperman 207,400 sh (New)
Steven Cohen 316,138 sh (New)
George Soros 193,000 sh (+235.65%)
Andreas Halvorsen 864,681 sh (+6.16%)
David Tepper 597,000 sh (+4.37%)
Steven Romick 1,042,910 sh (unchged)
Vanguard Health Care Fund 3,389,165 sh (unchged)
Robert Olstein 23,000 sh (unchged)
Mairs and Power 1,460 sh (unchged)
Prem Watsa Sold Out
First Eagle Investment Sold Out
Wallace Weitz 131,581 sh (-0.11%)
First Pacific Advisors 1,329,109 sh (-0.67%)
PRIMECAP Management 5,107,184 sh (-0.72%)
Diamond Hill Capital 1,087,616 sh (-1.22%)
Mario Gabelli 44,559 sh (-1.58%)
Signature Select Canadian Fund 35,650 sh (-3.26%)
Dodge & Cox 41,778 sh (-4.91%)
Jeremy Grantham 3,600 sh (-5.26%)
Ken Fisher 1,910 sh (-7.73%)
John Rogers 340,370 sh (-8.24%)
Pioneer Investments 1,950,853 sh (-10.76%)
Larry Robbins 2,962,743 sh (-10.96%)
Eaton Vance Worldwide Health Sciences Fund 143,715 sh (-9.02%)
» More
Q2 2018

TMO Guru Trades in Q2 2018

Ray Dalio 19,692 sh (New)
Paul Tudor Jones 5,777 sh (New)
Caxton Associates 5,390 sh (New)
Andreas Halvorsen 2,480,362 sh (+186.85%)
Mairs and Power 2,060 sh (+41.10%)
Leon Cooperman 258,400 sh (+24.59%)
Pioneer Investments 2,189,196 sh (+12.22%)
Jim Simons 377,044 sh (+3.94%)
Diamond Hill Capital 1,098,629 sh (+1.01%)
Robert Olstein 23,000 sh (unchged)
Jeremy Grantham 3,600 sh (unchged)
George Soros Sold Out
Wallace Weitz 131,424 sh (-0.12%)
PRIMECAP Management 5,087,754 sh (-0.38%)
Mario Gabelli 44,296 sh (-0.59%)
John Rogers 334,978 sh (-1.58%)
Dodge & Cox 41,098 sh (-1.63%)
David Tepper 585,000 sh (-2.01%)
Vanguard Health Care Fund 3,317,665 sh (-2.11%)
Steven Romick 984,150 sh (-5.63%)
First Pacific Advisors 1,248,706 sh (-6.05%)
Ken Fisher 1,720 sh (-9.95%)
Larry Robbins 2,546,601 sh (-14.05%)
Steven Cohen 10,000 sh (-96.84%)
Eaton Vance Worldwide Health Sciences Fund 134,961 sh (-6.09%)
» More
» Details

Insider Trades

Latest Guru Trades with TMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-06-30 Reduce -2.11%0.03%$203.14 - $219.53 $ 227.157%3,317,665
David Tepper 2018-06-30 Reduce -2.01%0.03%$203.14 - $219.53 $ 227.157%585,000
John Rogers 2018-06-30 Reduce -1.58%0.01%$203.14 - $219.53 $ 227.157%334,978
Leon Cooperman 2018-06-30 Add 24.59%0.37%$203.14 - $219.53 $ 227.157%258,400
Wallace Weitz 2018-06-30 Reduce -0.12%$203.14 - $219.53 $ 227.157%131,424
Mario Gabelli 2018-06-30 Reduce -0.59%$203.14 - $219.53 $ 227.157%44,296
Dodge & Cox 2018-06-30 Reduce -1.63%$203.14 - $219.53 $ 227.157%41,098
Ken Fisher 2018-06-30 Reduce -9.95%$203.14 - $219.53 $ 227.157%1,720
George Soros 2018-06-30 Sold Out 0.74%$203.14 - $219.53 $ 227.157%0
David Tepper 2018-03-31 Add 4.37%0.05%$192.98 - $224.11 $ 227.158%597,000
John Rogers 2018-03-31 Reduce -8.24%0.07%$192.98 - $224.11 $ 227.158%340,370
Leon Cooperman 2018-03-31 New Buy1.6%$192.98 - $224.11 $ 227.158%207,400
George Soros 2018-03-31 Add 235.65%0.52%$192.98 - $224.11 $ 227.158%193,000
Wallace Weitz 2018-03-31 Reduce -0.11%$192.98 - $224.11 $ 227.158%131,581
Mario Gabelli 2018-03-31 Reduce -1.58%$192.98 - $224.11 $ 227.158%44,559
Dodge & Cox 2018-03-31 Reduce -4.91%$192.98 - $224.11 $ 227.158%41,778
Ken Fisher 2018-03-31 Reduce -7.73%$192.98 - $224.11 $ 227.158%1,910
Prem Watsa 2018-03-31 Sold Out 0.02%$192.98 - $224.11 $ 227.158%0
First Eagle Investment 2018-03-31 Sold Out $192.98 - $224.11 $ 227.158%0
Vanguard Health Care Fund 2017-12-31 Reduce -4.13%0.06%$182.03 - $200.37 $ 227.1519%3,389,165
David Tepper 2017-12-31 Reduce -3.38%0.05%$182.03 - $200.37 $ 227.1519%572,000
John Rogers 2017-12-31 Reduce -3.48%0.03%$182.03 - $200.37 $ 227.1519%370,944
George Soros 2017-12-31 New Buy0.3%$182.03 - $200.37 $ 227.1519%57,500
Mario Gabelli 2017-12-31 Reduce -7.66%$182.03 - $200.37 $ 227.1519%45,275
Dodge & Cox 2017-12-31 Reduce -3.94%$182.03 - $200.37 $ 227.1519%43,937
Ken Fisher 2017-12-31 Add 63.64%$182.03 - $200.37 $ 227.1519%2,070
First Eagle Investment 2017-12-31 Reduce -99.94%0.15%$182.03 - $200.37 $ 227.1519%200
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541380    SIC: 3826
Compare:NYSE:DHR, XAMS:PHIA, NYSE:A, NYSE:IQV, TSE:6869, XSWX:LONN, NYSE:LH, NAS:IDXX, NYSE:DGX, XTER:SRT3, SZSE:300676, XPAR:BIM, XPAR:ERF, NYSE:PKI, NYSE:BIO, NYSE:QGEN, NAS:DXCM, NAS:ICLR, NAS:EXAS, XTER:AFX » details
Traded in other countries:TMOS34.Brazil, TN8.Germany, TMO.Mexico, TFS.Switzerland, 0R0H.UK,
Headquarter Location:USA
Thermo Fisher Scientific Inc is a healthcare company. It offers analytical instruments, laboratory equipment, software, services, consumables, reagents and chemicals.

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments: analytical technologies (about 22% of sales after the FEI acquisition); specialty diagnostic products (16%); life science solutions (26% including Affymetrix); and lab products and services (36% including Patheon and excluding cross-segment sales).

Guru Investment Theses on Thermo Fisher Scientific Inc

Weitz Funds Comments on Thermo Fisher Scientific - Jan 26, 2017

Thermo Fisher Scientific (NYSE:TMO) provides analytical instruments, equipment, reagents and consumables, as well as software and services for research, analysis, discovery and diagnostics across most of the globe. Thermo is well-diversified by both product and end market, boasting strong defensible market positions and reputable brands. Roughly three quarters of the company’s revenues are recurring in nature (consumables and services), consistent with our preference for subscription-like cash flow streams. Its portfolio of businesses is characterized by stable pricing, relatively acyclical organic growth and consistent excess cash generation. We believe the life sciences tools and diagnostics industry is a “good neighborhood,” characterized by relatively high entry barriers, high customer switching costs and rational competitive behavior. Currency headwinds and investor rotation toward more cyclically- exposed areas of the industrial and healthcare sectors left Thermo’s stock largely unchanged the past 18 months while our estimate of business value grew nicely. We took advantage, initiating a position at, what we believe is, an attractive valuation.



  • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

John Rogers Comments on Thermo Fisher Scientific Inc. - Jan 20, 2017

Also, scientific research supplier Thermo Fisher Scientific Inc. (NYSE:TMO) dropped –11.20% despite an earnings beat. The company reported earnings per share of $2.03 in late October, well ahead of the $1.97 consensus estimate; it also closed its acquisition of electron microscope maker FEI Company. Health care stocks were generally weak in November and December as investors rotated away from defensive stocks toward more aggressive ones. In our view, the company remains on the right track.

From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund fourth quarter 2016 commentary.

Check out John Rogers latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 38.37
TMO's PE Ratio is ranked lower than
56% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. TMO: 38.37 )
Ranked among companies with meaningful PE Ratio only.
TMO' s PE Ratio Range Over the Past 10 Years
Min: 12.67  Med: 26.52 Max: 41.23
Current: 38.37
12.67
41.23
Forward PE Ratio 18.76
TMO's Forward PE Ratio is ranked higher than
72% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TMO: 18.76 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 38.31
TMO's PE Ratio without NRI is ranked lower than
55% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. TMO: 38.31 )
Ranked among companies with meaningful PE Ratio without NRI only.
TMO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.48  Med: 26.57 Max: 41.16
Current: 38.31
13.48
41.16
Price-to-Owner-Earnings 25.23
TMO's Price-to-Owner-Earnings is ranked higher than
67% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. TMO: 25.23 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TMO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.21  Med: 18.96 Max: 28.5
Current: 25.23
9.21
28.5
PB Ratio 3.46
TMO's PB Ratio is ranked higher than
60% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. TMO: 3.46 )
Ranked among companies with meaningful PB Ratio only.
TMO' s PB Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.99 Max: 3.72
Current: 3.46
0.83
3.72
PS Ratio 3.98
TMO's PS Ratio is ranked lower than
53% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. TMO: 3.98 )
Ranked among companies with meaningful PS Ratio only.
TMO' s PS Ratio Range Over the Past 10 Years
Min: 1.24  Med: 2.57 Max: 4.27
Current: 3.98
1.24
4.27
Price-to-Free-Cash-Flow 24.89
TMO's Price-to-Free-Cash-Flow is ranked higher than
60% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. TMO: 24.89 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TMO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.2  Med: 19.84 Max: 31.21
Current: 24.89
10.2
31.21
Price-to-Operating-Cash-Flow 21.27
TMO's Price-to-Operating-Cash-Flow is ranked lower than
52% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. TMO: 21.27 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TMO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.72  Med: 17.06 Max: 25.8
Current: 21.27
8.72
25.8
EV-to-EBIT 32.68
TMO's EV-to-EBIT is ranked lower than
69% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. TMO: 32.68 )
Ranked among companies with meaningful EV-to-EBIT only.
TMO' s EV-to-EBIT Range Over the Past 10 Years
Min: 11  Med: 24.8 Max: 36
Current: 32.68
11
36
EV-to-EBITDA 19.71
TMO's EV-to-EBITDA is ranked lower than
51% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. TMO: 19.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
TMO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 14.8 Max: 21.5
Current: 19.71
6.8
21.5
EV-to-Revenue 4.81
TMO's EV-to-Revenue is ranked lower than
57% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. TMO: 4.81 )
Ranked among companies with meaningful EV-to-Revenue only.
TMO' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.3  Med: 2.85 Max: 5.2
Current: 4.81
1.3
5.2
PEG Ratio 2.92
TMO's PEG Ratio is ranked higher than
52% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.26 vs. TMO: 2.92 )
Ranked among companies with meaningful PEG Ratio only.
TMO' s PEG Ratio Range Over the Past 10 Years
Min: 0.55  Med: 1.7 Max: 3.32
Current: 2.92
0.55
3.32
Shiller PE Ratio 53.55
TMO's Shiller PE Ratio is ranked lower than
51% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. TMO: 53.55 )
Ranked among companies with meaningful Shiller PE Ratio only.
TMO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 20.78  Med: 41.7 Max: 62.7
Current: 53.55
20.78
62.7
Current Ratio 1.58
TMO's Current Ratio is ranked lower than
79% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. TMO: 1.58 )
Ranked among companies with meaningful Current Ratio only.
TMO' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.4 Max: 3.83
Current: 1.58
0.9
3.83
Quick Ratio 1.11
TMO's Quick Ratio is ranked lower than
84% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. TMO: 1.11 )
Ranked among companies with meaningful Quick Ratio only.
TMO' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.76 Max: 3.4
Current: 1.11
0.61
3.4
Days Inventory 81.37
TMO's Days Inventory is ranked lower than
51% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. TMO: 81.37 )
Ranked among companies with meaningful Days Inventory only.
TMO' s Days Inventory Range Over the Past 10 Years
Min: 65.13  Med: 69.62 Max: 82.46
Current: 81.37
65.13
82.46
Days Sales Outstanding 61.81
TMO's Days Sales Outstanding is ranked higher than
50% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. TMO: 61.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
TMO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.89  Med: 53.81 Max: 67.69
Current: 61.81
50.89
67.69
Days Payable 38.73
TMO's Days Payable is ranked lower than
67% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. TMO: 38.73 )
Ranked among companies with meaningful Days Payable only.
TMO' s Days Payable Range Over the Past 10 Years
Min: 31.3  Med: 32.57 Max: 45.43
Current: 38.73
31.3
45.43

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.29
TMO's Dividend Yield % is ranked lower than
93% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.81 vs. TMO: 0.29 )
Ranked among companies with meaningful Dividend Yield % only.
TMO' s Dividend Yield % Range Over the Past 10 Years
Min: 0.22  Med: 0.45 Max: 0.86
Current: 0.29
0.22
0.86
Dividend Payout Ratio 0.11
TMO's Dividend Payout Ratio is ranked higher than
94% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. TMO: 0.11 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TMO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.12 Max: 0.17
Current: 0.11
0.11
0.17
Forward Dividend Yield % 0.30
TMO's Forward Dividend Yield % is ranked lower than
93% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. TMO: 0.30 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.31
TMO's 5-Year Yield-on-Cost % is ranked lower than
93% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. TMO: 0.31 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TMO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.24  Med: 0.48 Max: 0.93
Current: 0.31
0.24
0.93
3-Year Average Share Buyback Ratio -0.10
TMO's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. TMO: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TMO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37.3  Med: -3.6 Max: 4.4
Current: -0.1
-37.3
4.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.64
TMO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
68% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. TMO: 1.64 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TMO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.5 Max: 43.11
Current: 1.64
0.59
43.11
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.15
TMO's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
59% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.86 vs. TMO: 2.15 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
TMO' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.74  Med: 1.33 Max: 8.21
Current: 2.15
0.74
8.21
Price-to-Median-PS-Value 1.55
TMO's Price-to-Median-PS-Value is ranked lower than
78% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. TMO: 1.55 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TMO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 0.73 Max: 1.47
Current: 1.55
0.22
1.47
Price-to-Peter-Lynch-Fair-Value 3.08
TMO's Price-to-Peter-Lynch-Fair-Value is ranked lower than
73% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. TMO: 3.08 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
TMO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.61  Med: 1.67 Max: 15.84
Current: 3.08
0.61
15.84
Earnings Yield (Greenblatt) % 3.06
TMO's Earnings Yield (Greenblatt) % is ranked higher than
69% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. TMO: 3.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TMO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8  Med: 4 Max: 9.1
Current: 3.06
2.8
9.1
Forward Rate of Return (Yacktman) % 15.31
TMO's Forward Rate of Return (Yacktman) % is ranked higher than
73% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. TMO: 15.31 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TMO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 13.8  Med: 18.9 Max: 26.4
Current: 15.31
13.8
26.4

More Statistics

Revenue (TTM) (Mil) $23,094.00
EPS (TTM) $ 5.92
Beta1.33
Volatility23.42%
52-Week Range $181.51 - 249.95
Shares Outstanding (Mil)402.80

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 23,763 24,868 24,793
EBIT (Mil $) 4,661 5,134 6,647
EBITDA (Mil $) 6,603 7,079 7,986
EPS ($) 7.31 8.61 10.09
EPS without NRI ($) 7.31 8.61 10.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.03%
Dividends per Share ($) 0.65 0.68 0.76

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}